

# Noonan Syndrome

- Ineke van der Burgt
- Human Genetics UMC Nijmegen
- The Netherlands

# What is Noonan syndrome?

## Defining syndromes:

- Patients placed centrally
- Consequences for the patient main determinant:
  - The phenotype
  - Natural history and complications
  - Mode of inheritance or risk of recurrence

*Hennekam, AmJMedGenet 2007*

# NOONAN SYNDROME

- First described in 1963  
by Jacqueline Noonan



Running Together:

- \*Characteristic Facies
- \*Pulmonary Valve Stenosis
- \*Short Stature




*A Heart of Gold Honored 2006*

# NS and the genes of the Ras- pathway

<i>Gene</i>	<i>Locus</i>	
<i>PTPN11</i>	12q24.1	(50%)
<i>SOS1</i>	2p22-p21	(10-15%)
<i>KRAS</i>	12p12.1	(<5%)
<i>RAF1</i>	3p25	(3-17%)

Duplication 12q24.1q24.23 --> NS  
 (Oleg A. Shchelochkov, 2008)

*BRAF, MEK1*



# Who has Noonan syndrome?

## NS Scoring systems

1981 Duncan (23 items)

1984 Preus

1992 Sharland

1994 van der Burgt




**Suggestive face**



**Typical face**

**Lessons from molecular analysis;  
unexpected insights for phenotypes**

# The face in *SOS1*+ NS



Zenker, *JMedGenet* 2007



# The face in *KRAS*+ NS



# The face in *RAF1+* NS



*Pandit, Nature Genetics 2007*



# The Heart in Noonan Syndrome

- PS most common CHD (20 - 50%),
- HCM in ca 20 – 30% and ASD in ca 10%
  
- PS more common in *PTPN11+* patients
  
- HCM more common in *RAF1+* patients
- PS less prevalent in *RAF1+* patients  
(*Pandit, 2007 Razaque,2007*)
  
- ASD less frequent in *SOS1+* patients  
(*Roberts, 2007*)


# The electrocardiogram in Noonan syndrome

Wide QRS complex

Left-axis deviation

Pathologic Q

Little R development over the left precordium




*Sanchez-Cascos 1983*

<b>Study group</b>	<b>PTPN11 + (n=56)</b>	<b>PTPN11 – (n=29)</b>	<b>P-value*</b>
<b>Abberant ECG (%)</b>	<b>30 (53,6%)</b>	<b>12 (41,4%)</b>	0,201
Number of ECG characteristics:			
1 ECG characteristic (%)	16 (28,6)	8 (27,6)	0,567
2 ECG characteristics (%)	12 (21,4)	3 (10,3)	0,166
3 ECG characteristics (%)	2 (3,6)	1 (3,4)	0,733
<b>4 ECG characteristics (%)</b>	<b>0 (0)</b>	<b>0 (0)</b>	-----
Kind of ECG characteristic:			
Wide QRS complex	0 (0)	0 (0)	-----
<b>Left-axis deviation (%)</b>	<b>27 (48,2%)</b>	<b>11 (37,9%)</b>	0,251
Pathologic Q (%)	3 (5,4)	2 (6,9)	0,559
<b>Little R development over the left precordium (%)</b>	<b>16 (28,6%)</b>	<b>4 (13,8%)</b>	0,103

# The electrocardiogram in Noonan syndrome


ECG findings not associated  
with a PTPN11 mutation  
or  
with a specific cardiac anomaly



Pre operative ECG in NS patient

**45%**    **Left-axis deviation**

**24%**    **Little R development over  
the left precordium**




Normal ECG

# Height in Noonan syndrome

- Normal length at birth
- Bone maturity and puberty delayed
- Final adult height; males 161 cm, females 152 cm (1986)

- Short stature more frequent in *PTPN11+*  
(Zenker,2003)
- Mild GH resistance in *PTPN11+*  
(Binder, 2005)
- Normal height more frequent in *SOS1+*  
(Tartaglia, 2007)



## Evolution of Height-SDS during GH treatment (n=29) mean (SD) (range)

	At start	After 1 year	At final height
National standards	<b>-2.9**</b> (0.7)(-4.1 - -1.8)	<b>-2.3**</b> (0.7) (-3.8 - -1.2)	<b>-1.6**</b> (0.8) (-3.0 - -0.3)
Noonan standards	<b>-0.1**</b> (0.7) (-1.4 - +1.2)	<b>+0.6 **/*</b> (0.8) (-1.0 - +2.1)	<b>+1.2 *</b> (0.9)(-1.1 - +2.9)

Mean age at start GH therapy      11 years

*PTPN11* +      n = 22

Boys      n = 21

(Noordam, 2008)



## NOONAN SYNDROME

### Other features

- “Webbed neck”
- Pectus car/excavatum
- Haematologic abnormalities
- Cryptorchidism
- Ophthalmologic and hearing abnormalities
- Ectodermal abnormalities
- Lymphatic vessel dysplasia
- Developmental delay / learning problems

# Bleeding diathesis

- Up to 55% of all cases
- One-third have one or more coagulation defects
- Results do not correlate with bleeding risk
  
- Easy bruising more common in *PTPN11*+ patients  
(Zenker,2003 Yoshida,2004)
  
- Roberts et al 2007: thrombocytopenia and/or easy bruising in *SOS1*+ patients
- Schubbert et al 2007: easy bruising in *KRAS*+ patient

# Myeloproliferative disorders (MPD)

- **Occasionally in NS patients**
- Specific mutations in *PTPN11* → (transient) JMML  
*Kratz et al 2005; 8 out of 19: 218C>T (T73I)*
- JMML and ALL reported in *KRAS*+ patients
- No MPD in *SOS1*+ patients reported
- No MPD in *RAF1*+ patients reported

# Cryptorchidism in Noonan syndrome

- 60 – 80% of all boys with NS  
in *PTPN11+*, *SOS1+*, *KRAS+* and *RAF1+* patients  
\* more frequent in *PTPN11+* (Zenker,2003)
- Familial NS *PTPN11+*: maternal: paternal = 3:1  
(Tartaglia,2005)
- Familial NS *SOS1+*: affected mothers and fathers

# Developmental delay / learning problems


## In general:

Mild motor delay (>70%)

Articulation problems (>70%)

Mild mental retardation 15-35%

Mean full scale IQ is 85



IQ scores in 35 children with NS, 1999

# Developmental delay/ learning problems

*PTPN11* hot spot mutation  
922A>G (Asn308Asp)

More regular education  
*Jongmans,2005*

*SOS1* mutations

Less MR/ special education  
*Tartaglia,2007 Zenker,2007*

*KRAS* mutations

Frequent developmental delay  
*Zenker,2007*

*RAF1* mutations

8/21 (mild) Mental retardation  
*Pandit,2007*



# Social cognition and psychopathology in Noonan Syndrome

10 adult Patients (5 male, 5 female)

*PTPN11* mutation in 6

*KRAS* mutation in 1

*SOS1* mutation in 1

Heart:

PS in 6

Cleft MV in 1

No Heart Defect in 3

GH treatment in 5

**No Mutation**

## **Results in first 10 persons with NS**

**Variability in IQ scores: 65 – 121**

**None met the criteria for ADHD/Pervasive Development Disorder**

**Social and emotional recognition and expression are moderately impaired**

**All patients were remarkably friendly, cooperative and willing to please**


**Tendency to desirable answering**

# Online Abstract Submission ESHG 2008

## 14 with NS

- NS with multiple giant cell lesions > *PTPN11+* and *SOS1+*  
*Beneteau et al*
- Low frequency of *PTPN11+* in Mexican patients with NS  
*Gonzalez-Huerta et al*
- NS with marfanoid habitus in *SOS1+* patient  
*Morin et al*
- NS phenotype in *BRAF+* patient  
*Nystrom et al*

# The Ras-MAPK pathway and the syndromes



Nystrom, J MedGenet, 2008